ValuEngine upgraded shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from a sell rating to a hold rating in a research note published on Thursday morning.
ALXN has been the topic of a number of other reports. Stifel Nicolaus increased their price objective on shares of Alexion Pharmaceuticals from $151.00 to $155.00 and gave the stock a buy rating in a research note on Friday, April 27th. Evercore ISI raised shares of Alexion Pharmaceuticals from an in-line rating to an outperform rating in a report on Monday, February 5th. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, April 10th. Nomura increased their target price on shares of Alexion Pharmaceuticals from $148.00 to $156.00 and gave the stock a buy rating in a report on Thursday, March 15th. Finally, Robert W. Baird set a $160.00 target price on shares of Alexion Pharmaceuticals and gave the stock a buy rating in a report on Thursday, March 15th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nineteen have given a buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $155.52.
Shares of Alexion Pharmaceuticals opened at $117.14 on Thursday, Marketbeat reports. The stock has a market cap of $26.28 billion, a price-to-earnings ratio of 22.70, a PEG ratio of 1.06 and a beta of 1.11. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.86 and a current ratio of 3.35. Alexion Pharmaceuticals has a 12-month low of $96.18 and a 12-month high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, April 26th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.50 by $0.18. The firm had revenue of $930.90 million for the quarter, compared to the consensus estimate of $920.50 million. Alexion Pharmaceuticals had a net margin of 14.46% and a return on equity of 13.70%. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period in the prior year, the company posted $1.38 earnings per share. analysts predict that Alexion Pharmaceuticals will post 6.28 EPS for the current fiscal year.
In related news, EVP Julie O’neill sold 1,625 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $119.83, for a total value of $194,723.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christopher J. Coughlin acquired 10,000 shares of the company’s stock in a transaction that occurred on Monday, April 30th. The stock was acquired at an average price of $120.79 per share, with a total value of $1,207,900.00. Following the acquisition, the director now owns 26,333 shares in the company, valued at $3,180,763.07. The disclosure for this purchase can be found here. 4.35% of the stock is owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in ALXN. Schwab Charles Investment Management Inc. raised its holdings in Alexion Pharmaceuticals by 6.6% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 906,805 shares of the biopharmaceutical company’s stock worth $108,445,000 after purchasing an additional 56,472 shares during the last quarter. State of Alaska Department of Revenue raised its holdings in Alexion Pharmaceuticals by 510.1% during the 4th quarter. State of Alaska Department of Revenue now owns 25,990 shares of the biopharmaceutical company’s stock worth $3,106,000 after purchasing an additional 21,730 shares during the last quarter. Hennessy Advisors Inc. bought a new position in Alexion Pharmaceuticals during the 4th quarter worth approximately $629,000. Boston Advisors LLC raised its holdings in Alexion Pharmaceuticals by 3.0% during the 4th quarter. Boston Advisors LLC now owns 149,241 shares of the biopharmaceutical company’s stock worth $17,848,000 after purchasing an additional 4,315 shares during the last quarter. Finally, Peregrine Capital Management LLC raised its holdings in Alexion Pharmaceuticals by 29.7% during the 4th quarter. Peregrine Capital Management LLC now owns 126,320 shares of the biopharmaceutical company’s stock worth $15,107,000 after purchasing an additional 28,900 shares during the last quarter. Hedge funds and other institutional investors own 92.40% of the company’s stock.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.